Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics will host a virtual key opinion leader event to present new insights on its lead candidate ATH434 for the treatment of Multiple System Atrophy, highlighting its potential as a first-in-class, disease-modifying therapy for this rare neurodegenerative condition with no approved treatments. The event will feature leading neurologists and company leadership discussing the MSA treatment landscape, Phase 2 clinical data, and high-level plans for a Phase 3 program, signaling continued clinical progress and strategic positioning in the MSA drug development space.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, with a particular emphasis on Multiple System Atrophy, a rare and rapidly progressive disorder with no approved therapies. The company’s lead candidate, ATH434, is positioned as a potential first-in-class therapy targeting this significant unmet medical need and aims to strengthen Alterity’s role in the neurodegeneration treatment landscape.
Average Trading Volume: 5,614,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.